艾塞那肽改善肥胖2型糖尿病患者生存质量的研究

目的探讨艾塞那肽注射治疗对肥胖T2DM患者生存质量的影响。方法纳入22例肥胖T2DM患者,采用36项简式健康调查和世界卫生组织生存质量测定简表评估患者基线和艾塞那肽注射治疗26周后的生存质量。结果2例患者退出试验。与基线比较,治疗26周后,体重、WC、FPG、HbA₁c均降低(P<0.05或P<0.01),躯体功能、情绪健康问题导致的角色限制、躯体健康领域(PHYS)、心理领域、社会关系领域和环境领域评分均升高(P<0.05或P<0.01)。Pearson相关分析显示,HbA₁c与PHYS呈负相关(r=-0.735,P=0.006)。结论艾塞那肽注射治疗能降低肥胖T2DM患者血糖和体重,并改善总体生存质量。

Improvements in quality of life with Exenatide treatment in obesity patients with type 2 diabetes mellitus

ObjectiveTo investigate the effect of Exenatide injection on the quality of life inobese patients with type 2 diabetes mellitus(T2 DM).enrolled in this observational study.They were treated with Exenatide and followed up for 26 weeks.Quality of life was measured by SF-36 and WHOQOL-BREF at baseline and after 26 weeks of Exenatide therapy.ResultsTwo patients withdrew from the trial.Compared with baseline,after 26 weeks of treatment,body weight,WC,FPG and HbA₁c all decreased(P<0.05 or P<0.01),and physical function,role restriction caused by emotional health problems,physical health(PHYS),psychological,social relations and environmental fields were increased(P<0.05 or P<0.01).Pearson correlation analysis showed that HbA₁c was negatively correlated with PHYS(r=-0.735,P=0.006).the blood glucose and body weight significantly but also greatly improve the quality of life in obesity patients with T2 DM.